Merrimack Pharmaceuticals Inc (MACK) Releases Earnings Results, Misses Expectations By $-0.04 EPS

Merrimack Pharmaceuticals Inc (MACK) reported quarterly earnings results on Thursday, Aug-4-2016. The company reported $-0.40 earnings per share for the quarter, missing the analyst consensus estimate by $-0.04. Analysts had a consensus of $-0.36. The company posted revenue of $33.68 million in the period, compared to analysts expectations of $30.98 million. The company’s revenue was up 58.3% compared to the same quarter last year. During the same quarter in the previous year, the company posted $-0.33 EPS.

Many Wall Street Analysts have commented on Merrimack Pharmaceuticals Inc. Robert W. Baird Initiated Merrimack Pharmaceuticals Inc on May 27, 2016 to “Neutral”, Price Target of the shares are set at $8.

Merrimack Pharmaceuticals Inc closed down -0.1 points or -1.72% at $5.72 with 17,95,146 shares getting traded on Tusday. Post opening the session at $5.82, the shares hit an intraday low of $5.55 and an intraday high of $5.8704 and the price fluctuated in this range throughout the day.Shares ended Tusday session in Red.

In a different news, on Jul 27, 2016, Birgit M. Schoeberl (Head of Discovery) sold 50,000 shares at $5.50 per share price. According to the SEC, on Mar 21, 2016, Michael E Porter (director) purchased 5,000 shares at $7.20 per share price. On Mar 1, 2016, William M. Mcclements (Head of Corporate Operations) purchased 2,000 shares at $5.72 per share price, according to the Form-4 filing with the securities and exchange commission.

Merrimack Pharmaceuticals Inc. is a biopharmaceutical company discovering developing and preparing to commercialize medicines consisting of therapeutics paired with companion diagnostics for the treatment of cancer. The Company has six targeted therapeutic oncology candidates in clinical development (MM-398 MM-302 MM-121 MM-111 MM-151 and MM-141). The Company’s most advanced program is its investigational agent MM-398. The Company also has multiple product candidates in preclinical development and a discovery effort advancing additional candidate medicines. The Company has an agreement to utilize its manufacturing know-how to develop manufacture and exclusively supply bulk drug to a third party who processes the drug into a finished product and commercializes it globally. The Company is also developing in vitro and in vivo companion diagnostics for use with each of its oncology therapeutic product candidates.

Merrimack Pharmaceuticals Inc

Leave a Reply

Merrimack Pharmaceuticals Inc - Is it time to Sell?

Top Brokerage Firms are advising their investors on Merrimack Pharmaceuticals Inc. Subscribe to MoneyFlowIndex.Org Pre-Market Alerts, You will be the first to know the street buzz.